ReviewF1000prime reports2014
Research priorities for the development and implementation of serological tools for malaria surveillance.
Review in F1000prime reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 76 citations in OpenAlex.
- Induction, decay, and determinants of functional antibodies following vaccination with the RTS,S malaria vaccine in young children.BMC medicine · 2022Trial
- Trial
- Comparative evaluation of four immunoassays for Plasmodium vivax serological detection using recombinant PvMSP1-42 antigen.PLoS neglected tropical diseases · 2026Article
- Simultaneous serological assessment of vector and pathogen exposure to support intervention monitoring and understand host-vector interactions.Malaria journal · 2026Article
- Serological evidence of continued exposure toFrontiers in microbiology · 2025Article
- Principal component analysis of the Serological response to Plasmodium Falciparum using a Multiplex bead-based assay in Nigeria.Scientific reports · 2024Article
- Revolution in malaria detection: unveiling current breakthroughs and tomorrow's possibilities in biomarker innovation.Annals of medicine and surgery (2012) · 2024Review
- A broadly cross-reactive i-body to AMA1 potently inhibits blood and liver stages of Plasmodium parasites.Nature communications · 2024Article
- Previous Malaria Exposures and Immune Dysregulation: Developing Strategies To Improve Malaria Vaccine Efficacy in Young Children.The American journal of tropical medicine and hygiene · 2024Article
- The effectiveness of malaria camps as part of the malaria control program in Odisha, India.Scientific reports · 2023Article
- Reduced polymorphism of Plasmodium vivax early transcribed membrane protein (PvETRAMP) 11.2.Parasites & vectors · 2023Review
- Serological surveillance on potentialFrontiers in cellular and infection microbiology · 2023Article
- Assessing Prevalence and Transmission Rates of Malaria through Simultaneous Profiling of Antibody Responses againstJournal of clinical medicine · 2022Article
- Quantification of the dynamics of antibody response to malaria to inform sero-surveillance in pregnant women.Malaria journal · 2022Article
- Surveillance of Plasmodium vivax transmission using serological models in the border areas of China-Myanmar.Malaria journal · 2022Article
- Household and individual level risk factors associated with declining malaria incidence in Meghalaya, India: implications for malaria elimination in low-endemic settings.Malaria journal · 2021Article
- Community-based molecular and serological surveillance of subclinical malaria in Myanmar.BMC medicine · 2021Article
- PvMSP8 as a NovelPathogens (Basel, Switzerland) · 2021Article
- Heterogeneity in response to serological exposure markers of recent Plasmodium vivax infections in contrasting epidemiological contexts.PLoS neglected tropical diseases · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Surveillance is a key component of control and elimination programs. Malaria surveillance has been typically reliant on case reporting by health services, entomological estimates and parasitemia (Plasmodium species) point prevalence. However, these techniques become less sensitive and relatively costly as transmission declines. There is great potential for the development and application of serological biomarkers of malaria exposure as sero-surveillance tools to strengthen malaria control and elimination. Antibodies to malaria antigens are sensitive biomarkers of population-level malaria exposure and can be used to identify hotspots of malaria transmission, estimate transmission levels, monitor changes over time or the impact of interventions on transmission, confirm malaria elimination, and monitor re-emergence of malaria. Sero-surveillance tools could be used in reference laboratories or developed as simple point-of-care tests for community-based surveillance, and different applications and target populations dictate the technical performance required from assays that are determined by properties of antigens and antibody responses. To advance the development of sero-surveillance tools for malaria elimination, major gaps in our knowledge need to be addressed through further research. These include greater knowledge of potential antigens, the sensitivity and specificity of antibody responses, and the longevity of these responses and defining antigens and antibodies that differentiate between exposure to Plasmodium falciparum and P. vivax. Additionally, a better understanding of the influence of host factors, such as age, genetics, and comorbidities on antibody responses in different populations is needed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.